Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.

Arthritis research & therapy

Volumn 11, Issue 4, 2009, Pages

  Nakou, Magda ^a   Katsikas, Georgios ^a   Sidiropoulos, Prodromos ^a   Bertsias, George ^a   Papadimitraki, Eva ^a   Raptopoulou, Amalia ^a   Koutala, Helen ^a   Papadaki, Helen A ^a   Kritikos, Herakles ^a   Boumpas, Dimitrios T ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CD19 ANTIGEN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; BLOOD; BONE MARROW CELL; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 73349104126     PISSN: None     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2798     Document Type: Article

References (0)